SLGL
NASDAQ HealthcareSol-Gel Technologies Ltd. - Ordinary Shares
Biotechnology
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
�� 市场数据
| 价格 | $78.08 |
|---|---|
| 成交量 | 101,921 |
| 市值 | 253.39M |
| 贝塔系数 | 1.130 |
| RSI（14日） | 62.0 |
| 200日均线 | $61.56 |
| 50日均线 | $73.12 |
| 52周最高 | $97.97 |
| 52周最低 | $8.00 |
| Forward P/E | -8.48 |
| Price / Book | 4.97 |
🎯 投资策略评分
SLGL 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (65/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🐋 Institutional Whale (5/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 SLGL in your text
粘贴任何文章、记录或帖子 — 工具将提取 SLGL 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-07-16.